NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Yes. My series limits itself to immunotherapeutic treatment products in oncology recently highlighted by the journal of neurooncology, plus 2 immonostimulants used by NWBO. The journal of neouro oncology article/table did not include Kite's contender. Probably because Novartis already is in its phase II trial with breakthrough therapy status. Regardless, both therapies do not expect to replace standard of care, and they instead expect to provide options to the 15% of patients that do not recover with soc. They are further limited to B-cell leukemias and lymphomas, only use one antigen, suffer from tumor escape, serious toxicities..... Moreover, they all have patent concerns. Their results are particularly striking initially because they are willing to sacrifice normal b-cell populations as well. Still, I'm very glad they are there right now for the 15% of children and adults who do not respond or suffer recurrence after soc followed by bone marrow transplants.